IO 103

Drug Profile

IO 103

Alternative Names: IO103; PD-L1 peptide vaccine

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IO Biotech
  • Developer Herlev Hospital
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Follicular lymphoma; Multiple myeloma

Most Recent Events

  • 22 Feb 2018 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Denmark (SC) (NCT03047928)
  • 12 Dec 2017 Phase-I clinical trials in Follicular lymphoma (Second-line therapy or greater) in Denmark (SC) (NCT03381768)
  • 31 Jan 2017 Preclinical trials in Cancer in Denmark (Parenteral) before February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top